Topic

Brent Herspiegel is the CEO of Herspiegel Consulting.

Beth Schurman is the COO of Herspiegel Consulting.

Articles

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.

When to Utilize Commercial Outsourcing 

O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.

Q&A With Kevin O'Neill, president and CEO of GE HealthCare, Pharmaceutical Diagnostics

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

Panel discusses what real-world evidence—and related patient-reporting technology—need to achieve to better influence payer decision-making. 

Pharma 2023: Unleash RWE Benefits Along the Value Chain

Webcasts

Webinar Date/Time: Tuesday, March 14 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET


Driving Your Organizations Success and Transformational Initiatives in Clinical Trials

Webinar Date/Time: Tuesday, February 28, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET

Do decentralized trials still offer clinical precision in challenging patient populations?

Webinar Date/Time: Tuesday, February 14, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET

Creating the Future in Clinical Research with CROs Using Real-World Data

 and can be reached at mrivers@mjhlifesciences.com.

One company pursues a program for a technology they believe is a potential cure for Type 1 diabetes.

Type 1 Diabetes: A Potential Cure

Webinar Date/Time: Tuesday, January 31st 2023 | 9 am CT | 10 am ET | 3 pm GMT | 4 pm CET

The conundrum of proliferating data from decentralized clinical trials

Webinar Date/Time: Tuesday, January 17th, 2023 at 9 am CT, 10 am ET, 3 pm BST, 4 pm CET



How to Accelerate Adoption and Lower TCO With a Configurable RTSM System

Mike Straus is a freelance writer based in British Columbia, Canada. His work has appeared in 

Nutritional Outlook, Hoist, and Massage Therapy Canada

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

R&D/Clinical Trials